Hormone Therapy News

Gender-affirming hormone therapy causes changes in HDL cholesterol levels for transgender adolescents, and obesity can modify these associations, according to a research letter published in JAMA Pediatrics.

The incidence of abnormal liver enzymes among transgender men and women prescribed gender-affirming hormone therapy is low, with no cases of symptomatic liver injury observed after 1 year of treatment, data show.

The FDA accepted a new drug application for an oral testosterone undecanoate softgel for the treatment of primary and secondary hypogonadism in men, according to a press release from Marius Pharmaceuticals.

Intramuscular injections resulted in higher levels of estradiol than oral and transdermal routes for transgender women, whereas all hormone therapy routes result in similar testosterone levels in transgender men, according to study data.

A supervised center-based exercise training program, not testosterone therapy, improved vascular function among middle-aged men with central adiposity, according to research published in Hypertension.

Compared with placebo, 2 years of testosterone therapy was associated with lower risk for type 2 diabetes among men with impaired glucose tolerance or newly diagnosed diabetes but no hypogonadism, according to trial data.

Eleven percent of transgender men using testosterone develop erythrocytosis, increasing their risks for blood clots, myocardial infarction and stroke, according to a study published in The Journal of Clinical Endocrinology & Metabolism.

Premenopausal women at high risk for ovarian cancer who experienced surgical menopause reported impaired cognition 6 months after surgery, but the decline was not sustained long term, according to study data.

Growth hormone therapy is safe for adults with Prader-Willi syndrome and leads to increased lean body mass and decreased fat mass, according to systemic review data published in Clinical Endocrinology.

Women who filled a prescription for female hormone therapy did not have an increased risk for retinal vein occlusion or retinal artery occlusion, according to findings published in JAMA Ophthalmology.